新里程(002219) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥932,134,661.99, a decrease of 1.05% compared to ¥942,006,366.62 in the same period last year[7] - Net profit attributable to shareholders was ¥26,899,235.72, down 47.62% from ¥51,357,567.04 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥24,026,919.39, a decline of 52.12% compared to ¥50,176,986.27 in the previous year[7] - Basic and diluted earnings per share were both ¥0.0144, down 47.64% from ¥0.0275 in the previous year[7] - The company reported a net loss of CNY 999,397,101.11 for the period, compared to a loss of CNY 979,173,497.37 in the previous period[40] - Total operating revenue for the current period is ¥932,134,661.99, a decrease of 1.0% from ¥942,006,366.62 in the previous period[41] - Net profit for the current period is ¥33,649,901.76, down 50.3% from ¥67,671,568.20 in the previous period[43] - Operating profit decreased to ¥59,716,502.89, a decline of 38.7% from ¥97,317,266.17 in the previous period[43] - The total comprehensive income for the current period is -¥4,964,883.14, compared to ¥66,879,664.14 in the previous period[44] Cash Flow and Liquidity - The net cash flow from operating activities was ¥101,220,316.55, a significant improvement from a negative cash flow of ¥8,666,208.61 in the same period last year[7] - Cash received from sales of goods and services was ¥845,637,677.40, a decrease from ¥914,404,711.96 in the previous period[50] - The net cash flow from financing activities was -¥143,248,277.39, reflecting increased debt repayments of ¥596,000,000.00 compared to ¥367,134,546.80 in the prior year[52] - The ending balance of cash and cash equivalents decreased to ¥237,711,312.75 from ¥413,957,872.27 year-over-year[52] - The company reported a significant increase in cash inflow from operating activities, rising to ¥106,006,083.55 from ¥3,136,216.23 in the previous year[55] - The cash outflow for operating activities was reduced to ¥15,511,273.10 from ¥97,926,590.60, indicating improved operational efficiency[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,841,307,875.56, an increase of 0.94% from ¥8,758,983,757.39 at the end of the previous year[7] - Total liabilities increased to CNY 5,988,622,609.80 from CNY 5,901,333,608.49, reflecting an increase of approximately 1.48%[34] - Current liabilities rose to CNY 3,027,142,930.49, up from CNY 2,964,779,474.64, indicating an increase of about 2.1%[34] - Long-term borrowings decreased to CNY 1,394,699,498.82 from CNY 1,588,827,002.10, a reduction of approximately 12.2%[34] - The total current assets were CNY 1,836,449,990.44[62] Shareholder Information - The top shareholder, Que Wenbin, holds 42.57% of the shares, amounting to 794,009,999 shares, which are pledged and frozen[10] - There were no significant changes in the number of shareholders or any repurchase transactions among the top shareholders during the reporting period[11] Non-Recurring Gains and Expenses - The company reported non-recurring gains totaling ¥2,872,316.33, primarily from non-current asset disposal and debt restructuring[8] - Research and development expenses skyrocketed by 5247.26% to ¥1.20 million, driven by increased investment in the Qili soft bag project[14] - Financial expenses rose by 81.68% to ¥45.36 million, due to increased loans and interest expenses[14] - Investment income increased by 266.77% to ¥7.19 million, resulting from the disposal of Guang'an Fuyuan and Guang'an Hengyuan hospitals[14] Regulatory Compliance and Commitments - The company reported a commitment to ensure the authenticity, accuracy, and completeness of information provided during the restructuring process, with strict adherence to commitments made in 2016[20] - The company has made long-term commitments regarding the authenticity of information provided by transaction parties during major asset restructuring, ensuring compliance with relevant regulations[20] - The actual controller of the company has committed to avoiding any competition with the company's business operations, ensuring that no competing activities will be undertaken by controlled entities[21] - The company has outlined measures to exit any potential competition that may arise from future business expansions, including ceasing operations or transferring competing businesses to unrelated third parties[21] - The company has confirmed that all commitments made are independently enforceable, and any violation resulting in losses will be fully compensated[21] - The company has reiterated its commitment to comply with relevant regulations regarding securities issuance and will not provide financial assistance or compensation to subscription targets[21] Other Financial Metrics - Cash and cash equivalents decreased by 31.55% to ¥237.71 million due to repayment of bank loans during the reporting period[14] - Other receivables increased by 40.03% to ¥129.77 million, attributed to new equity disposal collections[14] - Deferred tax assets decreased by 40.06% to ¥97.61 million, impacted by exchange rate fluctuations affecting the Australian subsidiary[14] - Prepayments increased by 66.38% to ¥89.35 million, reflecting a rise in hospital pre-collected inpatient fees[14] - Long-term payables surged by 350.10% to ¥358.16 million, indicating an increase in PRP long-term payables[14]